4DMT's 4D-150 heads toward 2-year DME data after 86% injection cut at 32 weeks
SPECTRA's interim results already showed 4D-150 cut aflibercept injections 86% versus projected need; the H2 2026 2-year data will test whether that durability holds.
Executive Summary
- 4D Molecular Therapeutics is heading toward a 2-year data readout for its gene therapy in diabetic macular edema, a milestone the company has flagged consistently since January 2026 and reaffirmed as of its most recent quarterly update.
- The trial's interim data at an earlier timepoint showed a reduction in anti-VEGF injection burden alongside a vision gain and no inflammatory safety signal, giving the company a specific effect to defend rather than an open question.
- Because no competing gene therapy has reached this indication in human testing, the 2-year data stand as the first durability test for the mechanism, and the read will hinge on whether the injection-frequency benefit holds as the studied population matures beyond the interim subset.
- A durable result would extend the company's gene-therapy platform's readthrough into its larger, registrational programs in wet age-related macular degeneration, where the same delivery approach is already in Phase 3 testing.
The catalyst
4D Molecular Therapeutics has guided to 2-year data from SPECTRA, the Phase 1/2 trial of 4D-150 in diabetic macular edema, in the second half of 2026. The company first flagged the timing in a January 7, 2026 corporate update and repeated the same H2 2026 window in its first-quarter 2026 disclosures, giving the guidance two independent confirmations rather than a single mention. The trial, registered as NCT05930561, enrolls 72 adult patients and remains Active, not recruiting, with a primary completion date of February 28, 2029. 4DMT+14DMT Provides Company Update and Anticipated Development Milestones for 2026Jan 7, 20264D-150 in Patients With Diabetic Macular EdemaNCT05930561
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the interim data showed
SPECTRA's Part 1 interim data, disclosed with a December 13, 2024 cutoff, reported a BCVA gain of 8.4 letters, a 194-micron reduction in central subfield thickness, and an 86% reduction in projected aflibercept injection burden relative to the aflibercept comparator, with a mean of 0.6 supplemental injections per patient and no intraocular inflammation observed. The trial's registered primary endpoints split by part: TEAE and SAE incidence in Part 1, and the annualized number of aflibercept injections in the study eye in Part 2, with secondary endpoints tracking BCVA and central subfield thickness through week 104. The 2-year data due in H2 2026 will report against that same injection-frequency and safety framework, at a timepoint that lets the interim signal be tested for durability rather than restated. NCT059305614D-150 in Patients With Diabetic Macular EdemaNCT05930561
Trial history
The trial moved from Recruiting to Active, not recruiting on September 22, 2025, the same date its primary completion date shifted by twelve months, from February 29, 2028 to February 28, 2029. Enrollment held flat at 72 patients across that period, a change the operational model characterizes as within the routine band for enrollment shifts. The registry shows one amendment event since the trial's 2023 start, a change frequency the protocol-stability read labels Stable. NCT059305614D-150 in Patients With Diabetic Macular EdemaNCT05930561
The competitive frame
No other gene therapy has reached human testing in diabetic macular edema alongside 4D-150; the closest modality match, AbbVie's surabgene lomparvovec, is being tested in diabetic retinopathy rather than DME, and a second AAV-based DME program from a Shanghai academic sponsor remains in Early Phase 1. The indication's active competitive field is instead dominated by anti-VEGF biologics, including Genentech's faricimab and Roche's ranibizumab, both already approved and in Phase 4 study, and EyePoint Pharmaceuticals' EYP-1901, a Phase 3 sustained-delivery candidate targeting the same injection-burden problem 4D-150 is addressing by gene therapy instead of repeat dosing. With no gene therapy having yet reported a durable, multi-year DME outcome, a 2-year result that holds the interim's injection-reduction magnitude would be the first human durability data point for this mechanism in the indication.
Regulatory context
The FDA cleared the SPECTRA IND in February 2023 and granted 4D-150 Regenerative Medicine Advanced Therapy (RMAT) designation for diabetic macular edema in May 2025, a designation carrying benefits similar to Breakthrough Therapy for cell and gene therapies. The company has said it expects to finalize a Phase 3 trial design for DME by mid-2026 and to start that global Phase 3 program in the second half of 2026, positioning the SPECTRA 2-year data as the bridge between the current Phase 2 signal and registrational testing. 4DMT4DMT Provides Company Update and Anticipated Development Milestones for 2026Jan 7, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.